XERS
Xeris Biopharma Holdings Inc

10,505
Mkt Cap
$1.57B
Volume
229.00
52W High
$10.03
52W Low
$2.82
PE Ratio
-45.65
XERS Fundamentals
Price
$9.70
Prev Close
$9.71
Open
$9.76
50D MA
$8.28
Beta
1.29
Avg. Volume
2.01M
EPS (Annual)
-$0.3736
P/B
-81.02
Rev/Employee
$515,406.09
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
More News
News Placeholder
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...
Business Wire·11d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·14d ago
News Placeholder
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·14d ago
News Placeholder
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains?
Xeris Biopharma (XERS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·18d ago
News Placeholder
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus
MariMed, Xeris Biopharma and Lam Research shine as Zacks' proven stock strategies continue to beat the market despite turmoil.
Zacks·21d ago
News Placeholder
Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
News Placeholder
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago

Latest XERS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.